Perspective Price Cash Flow Ratio from 2010 to 2024

CATX Stock   3.65  0.12  3.18%   
Perspective Therapeutics Price Cash Flow Ratio yearly trend continues to be fairly stable with very little volatility. Price Cash Flow Ratio will likely drop to -3.06 in 2024. During the period from 2010 to 2024, Perspective Therapeutics Price Cash Flow Ratio regression line of annual values had significance of  0.31 and arithmetic mean of (105.89). View All Fundamentals
 
Price Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
(2.91)
Current Value
(3.06)
Quarterly Volatility
118.39365774
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Total Revenue of 1.4 M or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 55.63, Dividend Yield of 0.0 or PTB Ratio of 1.36. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Perspective Therapeutics Correlation against competitors.
For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Latest Perspective Therapeutics' Price Cash Flow Ratio Growth Pattern

Below is the plot of the Price Cash Flow Ratio of Perspective Therapeutics over the last few years. It is Perspective Therapeutics' Price Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Cash Flow Ratio10 Years Trend
Pretty Stable
   Price Cash Flow Ratio   
       Timeline  

Perspective Price Cash Flow Ratio Regression Statistics

Arithmetic Mean(105.89)
Coefficient Of Variation(111.81)
Mean Deviation86.28
Median(58.68)
Standard Deviation118.39
Sample Variance14,017
Range412
R-Value0.28
Mean Square Error13,880
R-Squared0.08
Significance0.31
Slope7.51
Total Sum of Squares196,239

Perspective Price Cash Flow Ratio History

2024 -3.06
2023 -2.91
2022 -28.84
2021 -56.91
2020 -292.09
2019 -103.23
2018 -54.44

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Price Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Price Cash Flow Ratio(2.91)(3.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.